Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: A single-institution experience

Clinical Lung Cancer

Volumn 11, Issue 3, 2010, Pages 192-197

  Malhotra, Binu ^a   Evans, Tracey ^a   Weiss, Jared ^a   Eaby, Beth ^a   Stonehouse Lee, Susan ^a   Sherry, Victoria ^a   Langer, Corey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Central nervous system metastases; Chemotherapy naive; Epistaxis; Nonsquamous disease; Platinum

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 77952491738     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.025     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172:523-529
3. Schwartz AG, Prysak GM, Bock CH, et al. The molecular epidemiology of lung cancer. Carcinogenesis 2007; 28:507-518
4. Pirozynski M. 100 years of lung cancer. Respir Med 2006; 100:2073-2084
5. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3:819-831
6. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342:19-21. (Pubitemid 23183916)
7. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-1872
8. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a metaanalysis of the literature. Chest 1994; 106:861-865
9. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909.
10. Sculier JP, Berghmans T, Castaigne A, et al. Best supportive care or chemotherapy for stage IV non small cell lung cancer. In: Van Houtte P, Klastersky J, Rocmans P, eds. Progress and Perspectives in Lung Cancer. Berlin: Springer Verlag; 1999:199-207.
11. Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomized phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998; 34:1036-1044
12. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
13. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353
14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98
15. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three-platinum based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291
16. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218
17. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024
18. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d] pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992; 35:4450-4454
19. Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19:437-443
20. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998; 38:135-152
21. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597
22. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92:595-600.
23. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, AL- IMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11:435-440
24. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11:690-696
25. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005; 104:2449-2456
26. Grønberg B, Bremnes R, Aasebø U, et al. Pemetrexed carboplatin versus gem- citabine carboplatin in the treatment of stage IIIB/IV nonsmall cell lung cancer. J Clin Oncol 2007; 25(18suppl):388s (abstract 7517).
27. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
28. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440
29. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006; 355:2542-2550
30. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous nons-mall cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25(18 suppl):388s (abstract LBA7514).
31. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
32. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284-3289
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
34. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published piterature. J Clin Oncol 2005; 23:2926-2936
35. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51:335-345
36. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol 2001; 19:1734-1742
37. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009; 6:233-241
38. Comella P, Filippelli G, De Cataldis G, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007; 18:324-330
39. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52:155-163
40. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the PointBreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009; 10:252-256
41. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255-5261
42. Archer V, Reck M, Sandler AB, et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol 2008; 26(15 suppl):452s (abstract 8114).
43. Trial of bevacizumab (Avastin) plus pemetrexed (Alimta) and carboplatin in previously untreated advanced non-small cell lung cancer. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00254319. Accessed: March 17, 2010.
44. Skaff ZG, Hageboutros A, Krieger K, et al. A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer. J Clin Oncol 2009; 27(15 suppl): (abstract e19091).